UnitedHealth Lifts 2026 Guidance as Medical Expenses Ease
UnitedHealth reported third-quarter adjusted earnings of $4.69 per share, above analyst estimates, with revenue of about $112.7 billion. The company raised its 2026 adjusted profit forecast to at least $20.50 per share and said its medical care ratio improved to 88.4%, helping operating margin. It still faces declining Medicare Advantage enrollment, specialty drug costs, commercial insurance pressure and regulatory uncertainty.
UnitedHealth’s quarterly update, dated Oct. 13, 2026, showed adjusted profit of $4.69 a share against roughly $4.14 expected. Revenue was about $112.7 billion, little changed year over year, while net income was around $4.1 billion. Operating margin widened to 5.8% from 3.8%.
The medical care ratio fell to 88.4% from 89.9%, helped by about $610 million from better-than-expected costs tied to earlier periods. Even excluding that, Mizuho said the ratio beat expectations. Management raised 2026 adjusted EPS guidance to at least $20.50 and cited possible 2027 growth, though Medicare Advantage enrollment, specialty drug costs, commercial pressure and regulation remain concerns.
UnitedHealth’s improved margins and guidance could affect patients, employers, investors and providers. If medical costs keep moderating, the insurer may have more room to stabilize premiums or benefits, though specialty drug expenses and commercial pressures could still influence plan pricing. Declining Medicare Advantage enrollment may shape access and choices for older adults, while regulatory uncertainty could affect how plans operate. Investors may treat the results as evidence of recovery, but the durability of those gains—and their broader effect on healthcare costs—remains uncertain.